Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by mercedesmanon Jun 09, 2022 2:07pm
125 Views
Post# 34744545

RE:"Altercyte or Overcyte" EDTXF, the "PINK Planter" ......

RE:"Altercyte or Overcyte" EDTXF, the "PINK Planter" ......I guess, even the most gifted (those in the top 90% of all analysts), occassionally do make mistakes.  Like forgetting the main exchange a stock trades on, or what the price target is.

What is that 0.6 Analyst ranking mean ?  Does that mean he is rated at 6/10ths of 1 out of 10?

I thought it might be the ratio of the current SP to the Anlayst Target Price, but that's .15 (or for those that prefer fractions, about 1/7th)


It's a shame (sp sham?) that no other analysts want to be apart of a Biotech/medical device developer, involved in two very LATE stage Trials, each addressing unmet needs (for decades) in two multi-BILLION dollar markets.  Especially when the Trial results are "exceeding expectations", whilst  one at least, is in "confirmatory" and "3b" mode.


MM
<< Previous
Bullboard Posts
Next >>